Therapy of chronic hepatitis C virus infection in HIV co-infected people

Current Pharmaceutical Design

Volumn 10, Issue 17, 2004, Pages 2111-2122

  Fabris, P ^a   Barnes, E ^b   Tositti, G ^a   Giordani, M T ^a   Grasso, A ^c   de Lalla, F ^a  

^a San Bartolo Hospital   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c San Paolo Hospital   (Italy)

Author keywords

AIDS; HCV; HIV; Interferon; Ribavirin

Indexed keywords

ABACAVIR; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; NEVIRAPINE; PAROXETINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROPRANOLOL; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STAVUDINE; TACROLIMUS; ZALCITABINE; ZIDOVUDINE;

ANXIETY DISORDER; CELL COUNT; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ERUPTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; ECHOGRAPHY; ESOPHAGUS VARICES; EXPERIENCE; FATTY LIVER; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MONOTHERAPY; MORBIDITY; MORTALITY; MYOPATHY; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PATIENT MONITORING; PERSONALITY DISORDER; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; WEIGHT REDUCTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

EID: 3042551369     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384286     Document Type: Review

References (114)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Talal A. Opportunistic infections in HIV-infected individuals: hepatitis C virus. Lancet 2002; 360: 584-85.
3. Schreiber GB, Bush MP, Kleimman SH, Korelitz JJ. The risk of transfusion transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-90
4. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115: 764-68.
5. Soto B, Rodrigo L, Garcia-Bengoechea M, Sanchez-Quijano A, Riestra S, Arenas JI, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case: a multicenter study of 423 pairings. J Intern Med 1994; 236: 515-19.
6. Wyld R, Robertson JR, Brettle RP, Mellor J, Prescott L, Simmonds P. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 1997; 35: 163-66.
7. Graham CS, Baden LR, Yu E, Mrus W, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
8. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36: S201-S209.
9. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
10. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
11. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-28.
12. García-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-83.
13. Fabris P, Tositti G, Manfrin V, Giordani MT, Vaglia A, Cattelan AM, et al. Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients? J Acquir Immune Defic Syndr 2000; 25: 92-93.
14. Rockstroh JK, Spengler U, Sudhop U, Ewig S, Theisen A, Hammerstein U, et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs co-infected with HIV. Am J Gastroent 1997; 91: 2563-68.
15. Puoti M, Bonancini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 depletion in patients co-infected with hepatitis C and HIV. J Infect Dis 2001; 183; 134-37.
16. Bonancini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000; 160: 3365-73.
17. Bonancini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6: 203-8.
18. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect immunosuppression on composition of quasi-species population of hepatitis C virus in patients with chronic hepatitis C co-infected with human immunodeficiency virus. J Hepatol 1997; 26: 975-82.
19. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188: 2205-13
20. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, et al. HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolitic function. J Exp Med 2000; 192: 63-75
21. Talal AH, Canchis PW, Jacobson IM. The HCV and HIV co-infected patient: what have we learned about pathophysiology? Curr Gastroenterol Rep 2002; 4: 15-22.
22. Masur H, Kaplan JE, Holmes KK. U.S. Public Health Service; Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002 137: 435-78.
23. Cooper LC, Cameron W. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35: 873-9.
24. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment of human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viraemia in patients co-infected with HIV. J Infect Dis 1998; 177: 783-85.
25. Puoti M, Gargiulo F, Roldan EQ, Chiodera A, Palvarini L, Spinetti A, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 2000; 181: 2033-36.
26. Matsioda-Bernard P, Vrioni G, Onody C, Bernard L, de Turchis P, Perrone C. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. J Antimicrob Agents 2001; 17: 155-57.
27. Vento S, Garofano T, Renzini C, Casali F, Ferrraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-co-infected patients on antiretroviral combination therapy. AIDS 1998; 12: 116-117.
28. Zylberberg H, Chaix ML, Rabian C, Rouzioux C, Aulong B, Brechot C et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in co-infected subjects. Clin Infect Dis 1998; 26: 1104-1106.
29. Rockstroh JK, Theisen A, Kaiser R, Sauerbruch T, Spengler U. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs. AIDS 1998; 7; 12: 829-30.
30. Garcia-Samaniego J, Bravo R, Castilla J, Gomez-Cano M, Laguna F, Munoz F, et al. Lack of benefit of protease inhibitors on HCV viraemia on HIV-infected patients. J Hepatol 1998; 12: 829-830.
31. Zylberger H, Pialoux G, Carnot F, Landau A, Bréchot C, Pol S. Rapidly evolving hepatitis C virus-associated cirrhosis in HIV co-infected patients in relation to antiretroviral tritherapy. Clin Infect Dis 1998; 27: 1255-58
32. Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, et al. Immunologic dynamics in hemophiliacs patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000; 96: 4293-99.
33. Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 2000; 14: 212.
34. Ragni MV, Bontempo FA. Increase in hepatitis C viral load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999, 180: 2027-9.
35. Gavazzi G, Bouchard O, Leclercq P, Morel-Baccard C, Bosseray A, Dutertre N, et al. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virological responders? AIDS Res Hum Retroviruses 2000; 16: 1021-3.
36. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Liver fibrosis progression in HIV and hepatitis C virus co-infected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-87.
37. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12: 2289-2293.
38. Bra N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997; 349: 924-25.
39. Arribas JR, Ibanez C, Ruiz-Antoran B, Pena JM, Esteban-Calvo C, Frias J, et al. Acute hepatitis in HIV -infected patients during ritonavir treatment. AIDS 1998; 12: 1722-24.
40. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
41. Sulkowski MS, Thomas DL, Mehta SH, Chaisson R, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections Hepatology 2002; 35: 182-189.
42. Saves M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, et al. Hepatitis B and or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitors-contained antiretroviral regime in HIV-infected patients. Antimicrob Agents Chemother 2000; 44: 3451-55.
43. Martin-Carbonero L, Nunez M, Rios P, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002; 16: 1423-5.
44. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32: 259-67.
45. Bruno R, Sacchi P, Puoti M, Soriano V, Filice G. HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002; 97: 1598-606.
46. Saves M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations, Aquitaine Cohort, France, 1996-1998. Groupe d Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 13: F115-F121.
47. Boyer N, Marcellin P, Degott C, Degos F, Saimot AG, Erlinger S, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to HIV. Comite des Anti-Viraux. J Infect Dis 1992; 165: 723-726.
48. Marriott E, Navas S, del Romero J, Garcia S, Castillo I, Quiroga JA, et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Vir 1993; 40: 107-111.
49. Marcellin P, Boyer N, Behamou JP, Erlinger S. Interferon-alpha therapy for chronic hepatitis C in special patient populations. Dig Dis Sci 1996; 41: 126S-130S.
50. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Interferon alfa for the treatment of chronic hepatitis c in patients with HIV. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585-91.
51. Soriano V, Bravo R, Garcia-Samaniego J, Ortega E, Gonzalez J, Colmenero M, et al. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The hepatitis/HIV Spanish Study Group. J Infect 1997; 35: 225-30.
52. Mauss S, Klinker H, Ulmer A, Willers R, Weissbrich B, Albrecht H, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998; 26: 16-19.
53. Del Pozo MA, Arias JR, Pinilla J, Labarga P, Alcoba M, Martinez de la Cruz FJ, et al. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance, and response related factors. Hepatogastroenterology 1998; 45: 1695-01.
54. Rodrìguez-Torres M. Interferon alfacon-1 (infergen) treatment for prior interferon alfa-2a non-responders co-infected with hepatitis C virus and HIV. Hepatology 1999; 30: 626A.
55. Causse X, PAyen J, Izopet J, Bababny G, Girardin M. Does HIV-influence the response of chronic hepatitis to interferon treatment? J Hepatol 2000; 32: 1003-10.
56. Prestileo T, Mazzola G, Di Lorenzo F, Colletti P, Vitale F, Ferraro D, et al. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients. Int J Antimicrob Agents 2000; 16: 373-78.
57. Hayashi K, Fukuda Y, Nakano I, Katano Y, Yokozaki S, Toyoda H, et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 2000; 6: 677-81.
58. Bruno R, Sacchi P, Puoti M, Ciappina V, Zocchetti C, Brunetti E, et al. Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C. BMC Infect Dis 2002; 2: 17.
59. Hanabusa H. Efficacy of induction therapy with high-dose interferon for patients with hemophilia and human immunodeficiency virus-hepatitis C virus coinfection. Clin Inf Dis 2002; 35: 1527-33.
60. Di Martino V, Thevenot T, Boyer N, Cazals-Hatem D, Degott C, Valla D, et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS 2002; 16: 441-45.
61. Puoti M, Rossi S, El Hamad I, Ranieri S, CAdeo GP, Orani A, et al. Effect of treatment with interferon alpha on liver disease and survival in subjects with HIV-1 infection and chronic viral active hepatitis. Hepatology 1994; 20: 163A [Abstract 265].
62. Vento S, Di Perri G, Cruciani M, Garofalno T, Concia E. Rapid decline od CD4+ cells after IFN-α treatment in HIV-1 infection. Lancet 1993; 341: 958-59.
63. Pesce A, Taillan B, Rosenthal E, Garnier G, Vinti H, Dujardin P, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341, 1597.
64. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1494.
65. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus alfa 2b interferon plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352; 1426-32.
66. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235 1376.
67. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothimidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41: 1231-36.
68. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrobial Agent Chemother 1987: 31: 1613-17.
69. De Franceschi L, Fattovich, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anaemia induced by ribavirin therapy in patients with chronic hepatitis C vitus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
70. Balzarini J, Lee CK, Herdewijn P, De Clereq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′, 3′-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266: 21: 509-14.
71. Brinkman K, Ter Hofstede, H. Mithocondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev. 1999,1: 140-146.
72. Sulkowski M. Interferon plus ribavirin for chronic hepatitis C in HIV infected individuals. In: 37th Annual Meeting of the Infectious Diseases Society of America (IDSA). Philadelphia, Pennsylvania 1999 [Abstract S113].
73. Landau A, Batisse D, Van Huyen JP, Piketty C, Bloch F, Pialoux G, et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000, 14: 839-44.
74. Morsica G, De Bona A, Uberti C, Sitia G, Finazzi R, Lazzarin A. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS 2000, 14: 1656-58.
75. Suciu L, Goldman D, Jones J, Weisz K, Dieterik D. Sustained virological response following interferon and ribavirin therapy for hepatitis C patients who are co-infected with HIV. In 38th Annual Meeting of the Infectious Diseases Society of America (IDSA). New Orleans, Louisiana 2000 [Abstract 234].
76. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine M. Lack of interference between ribavirin and nucleoside analogues in HIV/HCV co-infected individuals undergoing concomitant anti-retroviral and anti-HCV combination therapy. AIDS 2000,14: 1857-58.
77. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, et al. Safety and efficacy of interferon-ribavirin combination therapy in HIV-HCV co-infected subjects: an early report. Gut 2000; 47: 694-97.
78. Dieterich DT, Suciu L, Goldman DJ Weisz KB, Jonea J. Sustained virological response (SVR) following interferon and ribavirin therapy for hepatitis C patients who are co-infected with HIV. In: 38th Annual Meeting of the Infectious Diseases Society of America (IDSA). New Orleans, Louisiana 2000 [Abstract 17].
79. Bini EJ, Rejd M, Manni RA. Safety and efficacy of interferon alpha- 2b and ribavirin combination therapy for the treatment of hepatitis C in patients co-infected with HIV. Hepatology 2001; 34: 335A [Abstract 653].
80. Pérez-Olmeda M, Asensi V, Romero M, Colmenero M., Sánchez-Montero F, Ochoa A. et al. Treatment of chronic hepatitis C: SHIRT (Spanish HIV Interferon Ribavirin Trial). In: 9th Conference on Retrovirus and Opportunistic Infections. Seattle, 2002 [Abstract 653].
81. Nasti G, di Gennaro G, Rizzardini G, Cadorin L, Tirelli U. Chronic hepatitis C in HIV-co-infected patients: feasibility and efficacy of interferon-alpha 2b and ribavirin combination therapy. J Acquired Immune Defic Syndr 2001: 26; 299-300.
82. Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, et al. Long term efficacy of combination therapy with interferon alpha-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001, 15: 2149-55.
83. Bochet M, De Torres MA, Valantin A, Thibault V, Poynard T, Katalama C, et al. Efficacy and tolerance of interferon plus ribavirin for chronic hepatitis C in HIV infected patients. In: 8th Conference on Retrovirus and Opportunistic infections. Chicago, February 2001 [Abstract 574].
84. Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Golz J, et al. German Clinical AIDS Working group (KAAD). Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 2002, 16: 2083-5.
85. Galeras JA, Tural C, Force L, Montoliu S, Rodriguez de Castro JA, Coll S, et al. Efficacy and safety of therapy with interferon alfa-2a+ ribavirin in HIV/HCV co-infected patients. Preliminary results of an open prospective study. 38th Annual meeting of the European Association for the Study of the Liver. J Hepatol 2003; 38 (Suppl 2): 482 [Abstract 487].
86. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, et al. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators. J Hepatol 2000; 33: 448-55.
87. Barnes E, Webster G, Whalley S, Dusheiko G. Predictors of a favorable response to alpha interferon therapy for hepatitis C. Clin Liver Dis 1999; 3: 775-91.
88. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001; 8: 414-20.
89. Cozzolongo R, Cuppone R, Giannuzzi V, Amati L, Caradonna L, Tamborrino V, et al. Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. Aliment Pharmacol Ther 2001; 15: 129-35.
90. Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clausen M, Pacheco DM, et al. Early HCV Viral Dynamics in HIV/HCV-Infected Patients on HCV treatment. In 9th Conference on Retrovirology and Opportunistic infections. Seattle, Washington 2002 [Abstract 121].
91. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin (RBV) for hepatitis C (HCV) in chronic hepatitis C-relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19: 67-75.
92. Poles M, Dieterich D. Hepatitis C /HIV coinfection: clinical management issues. Clin Infect Dis 2000; 31: 154-161
93. Dieterich DT. Treatment of Hepatitis C and anaemia in immunodeficiency virus-infected patients. J Infect Dis 2002; 185: S128-S137.
94. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-79.
95. Russo MW, Fried M. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-19.
96. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J. et al. Blunted trombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-29.
97. Kraus MR, Schafer A, Csef H, Faller H, Scheurlen M. Paroxetin for the treatment of the interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1091-99.
98. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281.
99. Gerard Y, Maulin L, Yazdanpanah Y, De La Tribonniere X, Amiel C, Maurage CA, et al. Symptomatic hyperlattacidemia: an emerging complication of antiretroviral therapy. AIDS 2000, 14; 2723-30.
100. Manns MP, McHutchison JG, Gordon SC, Shiff ER, Shiffman ML, Lee WM, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
101. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peg-interferon alta-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347: 975-82.
102. Pérez-Olmeda M, Núnez M, Romero M, Gonzalez J, Castro A, et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023-28
103. Chung RT, Anderson J, Alston B, Vallee M, Robbins G, Nel Vin T, et al. A randomised controlled trial of PEG-IFN alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG 5071. Seattle, Washington, In: 9th Conference on Retrovirology and Opportunistic infections 2002. [Abstract LB15].
104. Pol S, Perrone C, Carrat F, Banisadr F, Morand P, Lunel E, et al. ANRS HC02 and others. A randomised controlled trial of pegylated-interferon alpha-2b+ribavirin vs interferon alpha-2b+ribavirin in HIV co-infected patients. 38th Annual Meeting of the European Association of the Study of the Liver (EASL). J Hepatol 2003; 38, Suppl 2, 32 [Abstract 92].
105. Pol S, Carrat F, Hor TR, Deshayes J, Banisadr F, Rosenthal E, et al. High risk of mitochondriopathy in HIV/HCV co-infecyed patients under concomitant DDI/D4T and interferon (standard or pegylated IFN) ribavirin treatment. 38th Annual Meeting of the European Association of the Study of the Liver (EASL). J Hepatol 2003; 38 (Suppl 2): 117 [Abstract 399].
106. Cargnel A, Angeli E, Mainini A, Casella A, Gubertini G, Giorgi R, et al. Treatment of chronic hepatitis C in HIV infected patients (PTS) with PEG-IFN alpha 2b (PEG-IFN) plus ribavirin (RBV) versus pegylated interferon alpha 2b. 38th Annual Meeting of the European Association of the Study of the Liver (EASL). J Hepatol 2003; 38 (Suppl 2), 132 [Abstract 451].
107. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV cohort study. Lancet 2000; 356: 1800-5.
108. Cotler SJ, Jensen DM. Treatment of hepatitis C virus and HIV co-infections. Clin Liver Dis 2001; 5: 1045-61.
109. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97-100.
110. Gow PJ, Pillay D, Multimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72: 177-81.
111. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 3: 239-47.
112. Ascione A, De Luca M, Di Costanzo GG, Picciotto FP, Lanza AG, Canestrini C, et al. Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C. Curr Pharm Design 2002; 8(11): 977-80.
113. Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Design 2003; 9(18): 1475-81.
114. Bourinbaiar AS, Jirathitikal V. Low-cost anti-HIV compounds: potential application for AIDS therapy in developing countries. Curr Pharm Design 2003; 9(18): 1419-31.